Epcoritamab
from OncoPharm Hosted by John Bossaer
We discuss the newly approved CD20-CD3 T-cell engager for subcutaneous (SC) administration to treat DLBLC after 2 or more lines of therapy.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 15 minutes long.
When was this OncoPharm episode published?
This episode was published on May 25, 2023.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.